ZVRA High Tight Flag BreakoutNASDAQ:ZVRA
Forming a high tight flag on the daily on creasing volume. Big insider buy. Upcoming catalysts. Looking for 8.75 within the next 6 months.
www.tradingview.com
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.05 EUR
−101.92 M EUR
22.81 M EUR
55.48 M
About Zevra Therapeutics, Inc.
Sector
Industry
CEO
Neil F. McFarlane
Website
Headquarters
Celebration
Founded
2006
ISIN
US4884452065
FIGI
BBG009F52BQ7
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Zevra Therapeutics, Inc. stocks are traded under the ticker 1GDA.
We've gathered analysts' opinions on Zevra Therapeutics, Inc. future price: according to them, 1GDA price has a max estimate of 24.78 EUR and a min estimate of 15.38 EUR. Watch 1GDA chart and read a more detailed Zevra Therapeutics, Inc. stock forecast: see what analysts think of Zevra Therapeutics, Inc. and suggest that you do with its stocks.
1GDA reached its all-time high on Mar 3, 2021 with the price of 17.40 EUR, and its all-time low was 2.90 EUR and was reached on Jul 26, 2007. View more price dynamics on 1GDA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Zevra Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Zevra Therapeutics, Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
1GDA earnings for the last quarter are 1.03 EUR per share, whereas the estimation was 1.92 EUR resulting in a −46.55% surprise. The estimated earnings for the next quarter are −0.03 EUR per share. See more details about Zevra Therapeutics, Inc. earnings.
Zevra Therapeutics, Inc. revenue for the last quarter amounts to 21.97 M EUR, despite the estimated figure of 19.15 M EUR. In the next quarter, revenue is expected to reach 22.85 M EUR.
1GDA net income for the last quarter is 63.42 M EUR, while the quarter before that showed −2.86 M EUR of net income which accounts for 2.31 K% change. Track more Zevra Therapeutics, Inc. financial stats to get the full picture.
No, 1GDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 5, 2025, the company has 59 employees. See our rating of the largest employees — is Zevra Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zevra Therapeutics, Inc. EBITDA is −45.71 M EUR, and current EBITDA margin is −341.41%. See more stats in Zevra Therapeutics, Inc. financial statements.
Like other stocks, 1GDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zevra Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.